In this article, we will discuss the 5 Unrivaled Penny Stocks to Buy Now. For deeper discussion and analysis, read 10 Unrivaled Penny Stocks to Buy Now.
5. AMC Entertainment Holdings, Inc. (NYSE:AMC)
Number of Hedge Fund Holders: 16
Stock Price: $1.49
AMC Entertainment Holdings, Inc. (NYSE:AMC) received mixed analyst reactions on May 7 as Citi modestly raised its price target on the company to $1.20 from $1.10 while maintaining a Sell rating on the shares. The revised target reflects ongoing caution surrounding the company’s long-term profitability outlook despite improving theatrical attendance trends and recovering consumer demand for movie-going experiences.
On the same day, Benchmark upgraded AMC Entertainment Holdings, Inc. (NYSE:AMC) to Buy from Hold and assigned a $2.50 price target, citing improving box office conditions and structurally stronger per-patron economics. The firm noted that AMC is evolving from a liquidity recovery story into an earnings and cash flow recovery story as higher attendance levels and pricing power begin driving disproportionate adjusted EBITDA growth. Analysts also pointed to management commentary indicating that the level of box office revenue required for free cash flow breakeven is now materially lower than pre-pandemic thresholds, suggesting improved operational efficiency and cost management.
AMC Entertainment Holdings, Inc. (NYSE:AMC) is one of the world’s largest theatrical exhibition companies, operating movie theaters and premium cinema experiences across multiple global markets. Founded in 1920 and headquartered in Leawood, the company generates revenue primarily through ticket sales and high-margin food and beverage offerings. AMC has also invested heavily in premium viewing formats and enhanced theater experiences designed to attract consumers back to cinemas.
Improving industry fundamentals and stronger operational leverage could position the company to benefit if global box office recovery trends continue accelerating.
4. Solid Power, Inc. (NASDAQ:SLDP)
Number of Hedge Fund Holders: 19
Stock Price: $3.08
Solid Power, Inc. (NASDAQ:SLDP) reported first-quarter 2026 combined revenue and grant income of $3.1 million on May 5, primarily driven by an SK On site-acceptance milestone and progress under a U.S. Department of Energy assistance agreement. While revenue remains modest relative to operating expenses, the results demonstrate continued advancement in monetizing technical milestones and government-backed development programs. The company ended the quarter with approximately $435.3 million in total liquidity, supported by $121.3 million in net proceeds raised through a registered direct offering earlier in the year. Management noted that the company’s strong liquidity position is expected to provide sufficient runway to continue funding technology development initiatives, including construction of its SP2.5 production line, despite ongoing operating losses associated with early-stage commercialization efforts.
Earlier, on March 16, H.C. Wainwright analyst Amit Dayal initiated coverage on Solid Power, Inc. (NASDAQ:SLDP) with a Buy rating and a $7 price target. The analyst highlighted the company’s differentiated sulfide-based solid-state battery technology, which is designed to improve battery energy density, safety, and efficiency compared with conventional lithium-ion batteries. The firm also emphasized Solid Power’s strategic positioning within the rapidly expanding electric vehicle market and its focus on commercializing advanced electrolyte technologies.
Solid Power, Inc. (NASDAQ:SLDP) is a developer of next-generation all-solid-state battery technology intended for electric vehicles and other industrial applications. Founded in 2011 and headquartered in Louisville, the company specializes in sulfide-based solid-state batteries that replace the flammable liquid electrolytes used in traditional lithium-ion batteries. Its technology aims to deliver safer and higher-performing energy storage solutions for future transportation platforms.
The company’s sizable liquidity reserves and continued progress toward commercial-scale battery production may strengthen investor confidence in its long-term growth trajectory.
3. Veritone, Inc. (NASDAQ:VERI)
Number of Hedge Fund Holders: 21
Stock Price: $2.13
Veritone, Inc. (NASDAQ:VERI) announced on April 30 that Broadbean by Veritone’s Job Distribution platform had been adopted to support recruitment modernization and workforce optimization initiatives within the United Kingdom government. The deployment reflects increasing demand for AI-enabled hiring technologies capable of streamlining recruitment processes and improving talent acquisition efficiency across large organizations. Management described the adoption as a meaningful advancement in the use of enterprise artificial intelligence tools to address the growing complexity of modern workforce management.
Earlier, on April 21, Veritone, Inc. (NASDAQ:VERI) announced a collaboration with the Cold Case Foundation aimed at transforming how cold case investigations are conducted. Through the partnership, the organization is utilizing Veritone’s AI-powered Investigative Digital Evidence Management System to accelerate the analysis of evidence and improve case resolution efficiency. The technology is designed to process and organize large volumes of digital evidence, potentially helping investigators uncover insights more quickly while offering renewed hope to families seeking answers in long-unsolved cases.
Veritone, Inc. (NASDAQ:VERI) is an American artificial intelligence company focused on enterprise AI software and services. The company specializes in transforming unstructured audio, video, and text data into actionable intelligence through its proprietary aiWARE operating system. Veritone’s AI solutions are used across industries, including media, public sector, legal, and human resources, to automate workflows, improve analytics, and support operational decision-making.
The company’s growing adoption across government and investigative markets highlights the expanding practical use cases for enterprise artificial intelligence platforms.
2. X4 Pharmaceuticals, Inc. (NASDAQ:XFOR)
Number of Hedge Fund Holders: 26
Stock Price: $4.41
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) reported first-quarter revenue of $2.71 million on May 6, compared with analyst consensus estimates of $3.2 million. Management stated that its top priority remains the execution and enrollment of the pivotal Phase 3 4WARD trial evaluating mavorixafor in chronic neutropenia, with full enrollment expected by the end of the third quarter. The company also highlighted that the European Commission granted marketing authorization for XOLREMDI for patients with WHIM syndrome in the European Union. Executive Chairman Adam Craig noted that the approval reinforces the broader commercial and therapeutic potential of the company’s rare disease platform and will support future commercialization efforts through European partner Norgine.
Earlier, on April 29, X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) announced that the European Commission had formally approved Xolremdi capsules for the treatment of patients with WHIM syndrome across the European Union. Management described the approval as an important milestone that expands access to the therapy beyond the United States while validating the company’s targeted approach to treating rare hematologic disorders. In addition to ongoing commercialization efforts, the company continues advancing its global Phase 3 trial program evaluating mavorixafor in chronic neutropenia.
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) is a commercial-stage biopharmaceutical company focused on restoring immune system function through the development of novel therapies targeting rare diseases and hematologic disorders. Founded in 2014 and headquartered in Boston, the company develops precision medicines designed to address unmet medical needs in immunology and rare disease treatment markets.
The recent European regulatory approval and continued advancement of late-stage clinical programs could improve the company’s long-term commercial outlook and broaden global market opportunities. With 26 hedge funds maintaining exposure and shares trading near $4.41, XFOR may appeal to investors seeking biotech companies with regulatory momentum and rare disease catalysts.
1. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Number of Hedge Fund Holders: 29
Stock Price: $3.32
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) reported first-quarter revenue of $6.47 million on May 7, below analyst consensus estimates of $15.78 million. The company ended the quarter with approximately $665.2 million in cash, cash equivalents, and restricted cash, compared with $753.9 million at the end of 2025, while maintaining expectations that its cash runway will extend into early 2028. CEO Najat Khan stated that the company continues seeing strong execution across its portfolio, including encouraging initial safety and pharmacokinetic data from REC-1245 and the first patient dosing in REC-4539. Management emphasized that the progress demonstrates the company’s ability to translate biological and chemical insights generated by its AI-driven platform into differentiated clinical-stage programs.
Earlier, on April 30, JPMorgan Chase & Co. lowered its price target on Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) to $10 from $11 while maintaining an Overweight rating on the shares. The firm’s continued positive stance reflects confidence in the company’s long-term AI-enabled drug discovery platform despite near-term financial pressures and ongoing clinical development costs.
Recursion Pharmaceuticals is a clinical-stage TechBio company that integrates artificial intelligence, machine learning, and automation to industrialize drug discovery and development. Founded in 2013 and headquartered in Salt Lake City, the company focuses on decoding biology to identify treatments for rare diseases, oncology, and other areas with significant unmet medical needs. Its proprietary platform combines large-scale biological data analysis with advanced automation to accelerate therapeutic discovery.
The company’s substantial cash position and expanding clinical pipeline may provide flexibility to continue advancing multiple AI-driven drug programs despite ongoing development expenses.
While we acknowledge the potential of RXRX as an unrivaled penny stock, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than RXRX and that has 100x upside potential, check out our report about this cheapest AI stock.
READ NEXT: 8 Best Energy Infrastructure Stocks That Will Skyrocket and 10 Tech Stocks That Could Make You a Millionaire.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
